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Oral potentiallymalignant disorders (PMDs) are at risk of transforming to invasive squamous cell carcinoma (SCC), but controversy
exists over their management and the precise role of interventional treatment. In this study, a cohort of 100 patients presenting with
new, single oral dysplastic PMD lesions were followed for up to 10 years following laser excision. PMDs presented primarily as
homogeneous leukoplakias on floor of mouth and ventrolateral tongue sites and showed mainly high-grade dysplasia following
analysis of excision specimens. Sixty-two patients were disease-free at the time of the most recent followup, whilst 17 experienced
same site PMD recurrence, 14 developed further PMDs at new sites, 5 underwent same site malignant transformation, and 2
developed SCC at new oral sites. Whilst laser excision is an effective therapeutic tool in PMD management, prolonged patient
followup and active mucosal surveillance together with clear definitions of clinical outcomes are all essential prerequisites for
successful interventionalmanagement.Multicentre, prospective, and randomised trials of PMD treatment intervention are urgently
required to determine optimal management strategies.
1. Introduction
Oral potentially malignant disorder (PMD) is the preferred
WHO term to describe a number of mucosal lesions which
demonstrate an increased risk of squamous cell carcinoma
(SCC) development compared with apparently normal oral
mucosa.The list of mucosal pathology considered potentially
malignant includes discrete lesions such as leukoplakia and
erythroplakia, as well as more widespread conditions such as
proliferative verrucous leukoplakia, immunodeficiency, oral
submucous fibrosis, and perhaps more controversially oral
lichenoid lesions [1].
Whilst a vast literature exists describing the aetiology,
clinical appearance, and the identifiable histopathological
features of dysplasia seen in PMD, there remain no uni-
versally agreed clinical management protocols. We have
described previously, however, both the diagnostic accuracy
of obtaining definitive histopathology specimens and the
treatment efficacy of the entire lesion removal by interven-
tional laser surgery, and it is now generally accepted that
PMD excision is probably the optimal management option
[1–3].
It remains impossible, unfortunately, to predict either
the behaviour of individual PMD lesions or the progress
of disease in a particular patient, and some authors raise
concerns that formal PMD excision is not proven to prevent
SCC development, although it remains a not unreasonable
hypothesis [2, 3].
Of perhaps more significance is the lack of clarity regard-
ing overall clinical outcome following PMD treatment and
a need to both rationalise terminology and define a more
structured patient follow-up regime. The aim of this paper,
therefore, is to report on the detailed clinical outcome and
followup of a cohort of 100 PMDpatientswho all underwent a
standardised interventional laser surgery treatment to excise
dysplastic single lesion disease and whose postoperative
progress was documented for up to 10 years following the first
presentation.
2. Materials and Methods
2.1. Patients. Following ethical committee approval and
informed patient consent, 100 consecutive PMD patients
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attending the Maxillofacial Oncology/Dysplasia clinics at
Newcastle upon Tyne in Northern England over a 3-year
period and who underwent CO
2
laser excision of dysplastic
lesionswere recruited to the study.All were newpatients, with
no prior history of oral cancer or precancer and no previous
surgical or radiotherapy treatment, and all presented with
distinct, single-site PMD lesions proven on incisional biopsy
to exhibit dysplasia.
Laser surgery was carried out by the same operator (P.
J. Thomason) working to a standardised protocol, which
has been previously documented, and which comprised
formal excision of mucosal lesions and widespread ablation
of mucosal margins [2, 3]. The influence of risk factor
behaviour such as smoking and alcohol use was identi-
fied and appropriate cessation advice was given prior to
treatment. All patients were reviewed on a regular basis
postlaser intervention, at varying intervals between 1 and 12
months based upon the severity of individual clinical and
pathological features, tomonitor the clinical course of disease
and patients’ outcome. The identification of new mucosal
disease, biopsy for histopathological diagnosis, and further
interventional treatment was carried out in accordance with
defined management protocols [2, 3].
All excision biopsy specimens underwent standardised
histopathology examination by two experienced oral pathol-
ogists (C. M. Robinson and P. Sloan) working to agreed
diagnostic criteria. Lesions were graded using both the 2005
World Health Organisation (WHO) classification [4] and a
binary grading system (high grade versus low grade) that
benefits from increased levels of interobserver agreement
and improved predictive value [5]. The two pathologists
independently assessed the biopsy material, and discordant
grading was resolved by review and consensus. The size of
dysplastic lesions was assessed by multiplying the length by
width of laser excised specimens as recorded in histopathol-
ogy reports.
2.2. Clinical Outcome. Clinical outcome for each patient was
defined at the time of theirmost recent followup appointment
using one of the following terms:Clinical Resolution, a patient
clinically free of PMD disease following treatment, Persistent
Disease, whereby the PMD lesion persisted at the same site
despite interventional treatment, Recurrent Disease, when a
PMD lesion recurred at the same site following previously
successful excision, Further Disease, distinguishing PMD
lesion development at new oral sites following previously
successful excision,Malignant Transformation, whereby inva-
sive SCC arose at the same site of a clinically recognised
oral precursor lesion, and Oral Cancer Development, in
which invasive SCC development occurred but at new oral
sites distant from previously recognised or treated precursor
lesions.
2.3. Statistical Analysis. Statistical analyses were performed
using SPSS, version 19.0 (Statistical Package for the Social
Sciences, Chicago, IL, USA). Categorical variables for clinical
outcome data were summarized and presented descriptively
using frequencies and percentages with the chi-square test
Table 1: Anatomical site of PMD lesions.
Anatomical site Number of lesions
Floor of mouth 46
Lateral tongue 19
Ventral tongue 14
Soft palate 9
Buccal mucosa 5
Fauces 4
Alveolus 2
Retromolar 1
or Fisher’s exact test used to evaluate relationship between
variables. Continuous variables were expressed as mean ±
standard deviation and were compared using independent
Student’s t-test for pairwise comparison; Kruskal-Wallis test
was used for group comparison. Spearman’s correlation was
used to find and evaluate correlation between variables. The
Kaplan-Meier survival analysis method with log-rank test
was used to assess the differences between outcome groups
and to calculate cumulative disease-free survival rates. For all
tests, 𝑃 values ≤ 0.05were considered statistically significant.
3. Results
Sixty-eight male patients (age range 30–81 years; mean 58
years) and 32 female patients (age range 33–94 years; mean 59
years) comprised the study cohort. Eighty-six patients were
either current or ex-smokers, whilst 83 regularly consumed
alcohol. One hundred lesions were formally excised by laser,
the majority (76) appearing clinically as leukoplakias (67
homogeneous and 9 nonhomogeneous), and the remaining
were classified as erythroleukoplakias (16) and erythroplakias
(8). Most lesions (79) presented on the floor of mouth and
ventrolateral tongue, as summarised in Table 1.
Following consensus WHO grading of the excision spec-
imens, 42 of the lesions were classified as mild dysplasia,
whilst the remainder showed moderate dysplasia (26), severe
dysplasia (21), or carcinoma in situ (11) (Kappa value =
0.644, 𝑃 < 0.001). Consensus classification using the binary
grading system confirmed 56 of the moderate, severe, and
carcinoma-in-situ groups as “high grade” and 44 (42 mild
and 2moderate) as “low-grade” lesions (Kappa value = 0.756,
𝑃 < 0.001).
Following laser excision of their PMD lesions, patients
were reviewed for between 2 and 10 years with a mean
followup of around 5 years. Nearly two-thirds of cases
(62 patients) were completely disease-free following laser
surgery, whilst 17 had developed recurrent (same site) disease,
14 further (new site) disease, 5 same site malignant transfor-
mation, and 2 developed SCC at new oral sites distinct from
their original presenting PMD.No cases in this patient cohort
exhibited persistent disease following laser excision.
A number of clinicopathological features were examined
in detail for significance in relation to the documented
clinical outcome for the 100 PMD patients.
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3.1. Age. Chi-square testing revealed no significant relation-
ship between patient age and observed clinical outcome
(𝑃 = 0.361), although middle-age patients (41 to 62 years
of age) were predominant in all outcome groups. No SCC
development at new sites was seen in patients younger than
40 years.
3.2. Sex. Although more male patients presented with PMD
lesions, there were no statistically significant associations
seen between sex and treatment outcomes in this study (𝑃 =
0.811; chi-square test).
3.3. Clinical Appearance. The vast majority of lesions in
this study were leukoplakias, and there were no significant
clinical outcome differences discernible between these and
lesions with erythroplakic or erythroleukoplakic appearance
(𝑃 = 0.234, Fisher’s exact test). Whilst clinical appearance
was not significantly related to histopathological diagnosis,
non-homogeneous leukoplakia did show higher rates for
both recurrent and further dysplastic lesions compared to
homogeneous lesions (𝑃 = 0.016, chi-square test).
3.4. PMD Site. Most lesions presented on the floor of the
mouth and/or ventro-lateral tongue, with a significant rela-
tion seen between clinical outcome and anatomical site of
origin (𝑃 = 0.020, chi-square test), whereby the majority
of recurrent and further dysplastic disease cases were seen
on the floor of the mouth and ventral tongue. The single
dysplastic retromolar lesion in this study underwent malig-
nant transformation, whilst new site SCC development only
occurred in patients presenting initially with ventro-lateral
tongue lesions.
3.5. PMD Lesion Size. A significant relation was found
between clinical outcome and PMD lesion size, categorised as
<200mm2, between 200 and 600mm2 and >600mm2 (𝑃 =
0.010, chi-square test). Clinical resolution was most com-
monly seen inminor and intermediate sized lesions. A higher
mean size of presenting lesionwas seen in patients developing
recurrent disease (393.63mm2) compared to recurrence-free
(281.70mm2), albeit nonsignificant (𝑃 = 0.356, independent
t-test). Further (new site) dysplastic disease was significantly
more common following intermediate sized precursor lesion
excision (𝑃 = 0.049, chi-square test).
Although (same site)malignant transformationwasmore
common following intermediate sized lesion excision, this
was not statistically significant (𝑃 = 0.593, Chi-Square
test). However, risk estimate showed that if initial dysplasia
size exceeded or equalled 425mm2 (equivalent to the third
quartile), the odds ratio for transformationwas 2 times higher
than that of smaller sized lesions (95% CI, 0.365–11.582).
SCC development distant from primary lesion sites was
only seen in intermediate ormajor sized lesions, and although
nonsignificant (𝑃 = 0.104, Fisher’s exact test), there was a
definite trend for lesions>200mm2 to exhibit further disease,
malignant transformation, and SCC development following
treatment.
3.6. Smoking Behaviour. The vast majority of patients in this
study were either current or ex-smokers, and a significant
relation was found between smoking status and clinical
outcome (𝑃 = 0.014, chi-square test), whilst the incidence of
both recurrent and further disease was the highest in patients
exposed to tobacco, there was a trend for nonsmokers to
riskmalignant transformation and particularly SCC develop-
ment, whereby new site carcinomas were seen exclusively in
nonsmokers.
Nonsmoking patients also presented with significantly
larger lesions (mean size 473.20mm2), compared with
both ex-smokers (354.25mm2) and current smokers
(241.49mm2),𝑃 = 0.026, Kruskal-Wallis test. Also, Spearman
correlation revealed a significant positive correlation between
the degree of histopathological grading and lesion size
(𝑟 = 0.272; 𝑛 = 96; 𝑃 < 0.01), whereby increased PMD size
was associated with increased dysplasia severity.
Chi-Square testing, however, showed no significant rela-
tion between clinical outcome and the number of cigarettes
smoked per day (𝑃 = 0.139).
3.7. Alcohol Use. There were no statistically significant rela-
tionships seen between alcohol intake and outcome (𝑃 =
0.267, chi-square test), although patients consuming regular
alcohol posttreatment risked both recurrent and further
disease development, whilst all 3 patients who ceased alcohol
consumption remained disease-free.
3.8. Histopathological Grading. The WHO system showed
a significant relationship with defined outcome categories
(𝑃 = 0.003, Chi-Square test); patients exhibiting malignant
transformation or new site SCC development displayed were
those seen with either severe dysplasia or carcinoma-in-situ
in presenting PMDs.
Recategorising clinical outcome as either clinical resolu-
tion (disease free) or further disease (encompassing recur-
rent/further PMDs,malignant transformation, or SCC devel-
opment) emphasised that lesions with severe dysplasia and
carcinoma-in-situ were statistically more likely to develop
further disease (𝑃 = 0.010, chi-square test). The degree
of dysplasia also had a significant effect on unfavourable
outcome, with severe dysplasia/carcinoma-in-situ having a
shorter mean time to develop further disease (40 months)
compared with moderate (78.8 months) or mild dysplasia
(87.83 months). Also, 2- and 5-year disease-free survival rates
were much lower for severe dysplasia/carcinoma-in-situ than
for eithermoderate ormild dysplasia (63%, 76%, and 85% and
14%, 59%, and 62%, resp.), 𝑃 = 0.006, Log-Rank test. These
data are presented in Figure 1.
In terms of binary grading, there were demonstrably
more high-grade lesions in the outcome groups of recurrent,
further disease, malignant transformation, and SCC develop-
ment, but this was statistically significant only for recurrent
disease (𝑃 = 0.025, Fisher’s exact test). Increased statistical
significance was seen, however, by recategorising outcome as
either clinical resolution or further disease, confirming an
increased risk of further disease with high-grade lesions (𝑃 =
0.021, chi-square test). Patients with high grade dysplasia
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Figure 1: Kaplan-Meier analysis plotting disease-free survival
according to the WHO grading of dysplasia (𝑃 = 0.006, Log-rank
test).
also had a significantly shorter mean time (64 months) to
develop an unfavourable outcome compared to low-grade
lesions (88.7 months), and lower 2- and 5-year disease-free
survival rates were seen for high-grade compared to low-
grade dysplasia (68% versus 83% and 29% versus 63%, resp.),
𝑃 = 0.013, Log-Rank test. These data are summarised in
Figure 2.
3.9. Laser Excision Margin Analysis. Fourty eight PMD
excision specimens had clear margins on histopathological
examination with no discernible dysplastic features, whilst in
23 cases foci ofmild dysplasia were identified; less commonly,
moderate (14) and severe dysplasia (12) or rarely foci of
carcinoma-in-situ (3) were reported. Additional interven-
tion for dysplasia positive margin cases was not usually
required due to active ablation of all margins at the time of
laser excision, although all cases underwent careful clinical
surveillance.
Whilst the presence of dysplasia in excision margins did
not significantly influence overall postlaser surgery clinical
outcome (𝑃 = 0.053, Fisher’s exact test), the majority of
patients free from either recurrent (same site) disease or
further (new site) disease had clear resection margins, whilst
those developing further disease primarily exhibited severe
dysplasia in excisionmargins (𝑃 = 0.004 and𝑃 = 0.050, resp.,
chi-square test).
3.10. Length of Followup. Clinical outcome in relation to
length of followup was determined by plotting PMD-free
survival via Kaplan-Meier survival analysis, and this showed
a clear relationship with time. Figure 3 confirms that whilst
88 patients exhibited clinical resolution and were disease-free
1 year after surgery, there was a progressive rise in recurrent
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Figure 2: Kaplan-Meier analysis plotting disease-free survival
according to high- and low-grade dysplasia (𝑃 = 0.013, Log-Rank
test).
and further disease through successive years so that disease-
free rates fell to 75 at 2 years, 68 at 3 years, and 47 at 5 years,
with only 42 patients PMD-free 10 years after surgery.
Figure 4 shows that recurrent (same site) PMDs most
commonly presented during the first 2 years following laser
surgery (11 out of 17 cases), 𝑃 = 0.0001, Log-Rank test.
In contradistinction to recurrence, Figure 5 illustrates that
further (new site) PMDdisease could arise at any time during
the first five years of followup, butwith particularly significant
risk at 1 and 3 years after surgery, 𝑃 = 0.0001, Log-Rank test.
Five malignant transformation cases (same site) occurred
during the first 15 months of followup (𝑃 = 0.0001, Log-
Rank test), Figure 6. SCC development (new site cancer) only
occurred in 2 cases, both nearly 5 years following severe
dysplasia excision from the ventro-lateral tongue.
3.11. Risk Profiling. The clinico-pathological profile of PMD
cases observed in each clinical outcome category is sum-
marised in Table 2. Further statistical analysis was performed
using univariate and multivariate logistic regression analysis
to predict the role of patient age, sex, lesion size, type,
histopathology, anatomical site, and resection margin status
upon unfavourable clinical outcome (disease active state
including recurrent or further dysplasia, malignant transfor-
mation, and OSCC development), Table 3.
Whilst patients’ age and sex showed no significant effects,
non-homogenous leukoplakia was a significant predictor
of active disease (𝑃 = 0.023), increasing risk by nearly
3 times compared to homogenous lesions. Tongue lesions
showed a 3.4 increased risk compared with floor of mouth
(𝑃 = 0.013). The presence of severe dysplasia was a highly
significant predictor of active disease status (𝑃 = 0.007);
severe dysplasia and carcinoma-in-situ showed a 4.6 and a 4.8
times increased risk, respectively, for active disease compared
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Table 2: Risk profile and clinical outcome.
Clinical
resolution
Recurrent
disease
Further
disease
Malignant
transformation
OSCC
development
Number of cases 62 17 14 5 2
Sex
Male/female 39/23 13/4 10/4 3/2 1/1
Age (Yrs)
Mean (range) 57 (33–71) 58 (40–77) 59 (39–76) 63 (58–76) (47–48)
Lesion size (meanmm2) Minor (251) Major (394) Major (343) Intermediate/major(361) Major (478)
Pathology grading (binary system)
Low/high 35/27 4/13 6/8 2/3 0/2
Tobacco use1 Intermediate Heavy Heavy None None
Alcohol use2 Light Heavy Heavy None Light
1Heavy smoker > 20 cigarettes/day, intermediate smoker 10–20 cigarettes/day, and light smoker < 10 cigarettes/day.
2Heavy drinker > 28 units/wk, intermediate drinker 15–28 units/wk, and light drinker < 14 units/wk.
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Figure 3: Kaplan-Meier analysis plotting overall disease-free sur-
vival.
to mild dysplasia. High-grade dysplasia was also a significant
predictor for disease active state (𝑃 = 0.020), increasing the
risk to approximately 3 times that of low-grade dysplasia,
Table 3.
The presence of dysplasia in surgical resection margins
was also a significant prognostic factor for disease active
status (𝑃 = 0.035), increasing risk by nearly 3 times compared
with clear margins. Major sized lesions displayed a 4.5 times
increased risk compared to minor sized ones (𝑃 = 0.045),
Table 3.
4. Discussion
The ability to predict clinical outcome for PMDs remains
elusive in clinical practice, probably due to lack of under-
standing of the natural history of the disease, confusion over
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Figure 4: Kaplan-Meier analysis plotting disease-free survival for
recurrent (same site) disease and recurrence-free patients (𝑃 =
0.0001, Log-Rank test).
terminology, limited agreement on therapeutic interventions,
and uncertainty regarding patient followup. This paper is
unique in presenting detailed, long-term clinical outcome
data for a 100 patient cohort presenting with dysplasia-
proven PMDs, all excised by laser to a standardised treatment
protocol. We also define clinical outcome categories and
identify predictive clinico-pathological features. It is notable
upon reviewing the literature that many previous authors
have not found PMD clinical appearance, anatomical site,
histopathological assessment, or features related to patient
age, gender, or risk factor behaviour to reliably predict clinical
outcome [1, 6–10].
The ultimate goal of PMD diagnosis and management
must, of course, is the prevention of SCC. Malignant trans-
formation rates varying widely between 0.1 and 40% have
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Table 3: Logistic regression models for “disease active” status.
Outcome Risk factors Univariate analysis Multivariable analysis
Odds (95% CI) 𝑃 value Odds (95% CI) 𝑃 value
Disease active:
recurrent or
further
dysplasia,
malignant
transformation,
and OSCC
development
Age 1.007 (0.976–1.040) 0.646
Sex
Females Reference category
Males 1.448 (0.806–3.455) 0.405
Leukoplakia types
Homogenous Reference category
Nonhomogenous 2.991 (1.160–7.713) 0.023 3.319 (0.799–13.779) 0.099
PMDs site
FOM Reference category
Tongue 3.381 (1.292–8.845) 0.013 3.323 (0.775–14.241) 0.106
Other remaining sites 2.893 (0.971–8.620) 0.057 0.944 (0.171–5.218) 0.947
Histopathology (WHO grading)
Mid dysphasia Reference category
Moderate 1.129 (0.350–3.641) 0.839 1.960 (0.419–9.167) 0.393
Severe 4.622 (1.527–13.990) 0.007 5.994 (1.282–28.018) 0.023
CIS 4.800 (1.123–20.479) 0.034 17.104 (2.427–120.561) 0.004
Binary grading
Low grade Reference category
High grade 2.828 (1.182–6.678) 0.020
Resection margin
Free margins Reference category
Dysplastic margins 2.812 (1.073–7.371) 0.035 6.562 (1.545–27.878) 0.011
PMDs size (mm2)
Minor < 200 Reference category
Intermediate 200–600 2.327 (0.944–5.740) 0.067
Major > 600 4.464 (1.035–18.394) 0.045
been quoted in the literature, which is extremely unhelpful in
individual patient management, although the highest risk of
cancer development is believed to occur in the most dysplas-
tic precursor lesions; larger mucosal lesions and nonsmoking
patients also appear to be at enhanced risk of malignancy
[7, 8, 11, 12].
A number of observational, anecdotal, and retrospective
papers have reported clinical outcome and malignant trans-
formation data through the years, but these are significantly
weakened by the heterogeneous clinical and histopathologi-
cal nature of the precursor lesions studied and by a lack of
any agreed treatment protocols and uncoordinated follow-up
regimes. Table 4 lists themalignant transformation rates seen
in the dysplastic lesions reported in these studies; none of the
studies distinguished between same site and new site cancer,
but overall malignant transformation rates in excess of 36%
(with a mean of 16%) were reported, which are significantly
higher than either the 2 new site SCC cases or the 5 same site
malignant transformations seen during this study [9, 13–20].
More recently, Mehanna et al. quoted a 12% cancer
rate over a mean transformation time of 4.3 years using a
systematic review andmeta-analysis which included a total of
992 cases although interestingly, because of limitations in the
published literature, they only felt able to include 14 papers
out of a possible 2837 identified oral precancer publications.
The authors reported a lack of high quality evidence to date
which limited the scope of their study [21].
To date, there has been a paucity of prospective, ran-
domised controlled trials in oral precancer research, and
those that do exist have not fundamentally resolved treatment
and clinical outcome dilemmas.This 100 patient cohort study,
although not a controlled trial population, is a unique data
set facilitating analysis of a defined oral precancer population
with shared risk factor behaviour presenting with proven
dysplastic PMDs, standardised diagnostic and treatment pro-
tocols, consistent clinical decision making, and longitudinal
patient observation with documented clinical followup.
Whilst interventional laser excision of mucosal dysplastic
lesions appears to reduce the risk of same site malignant
transformation, SCC development at new sites remains a
risk reflecting field change in PMD disease [2, 3, 10].
Active mucosal surveillance and regular clinic follow up
remain mandatory for all PMD patients, and interventional
management strategies are best regarded as cyclical, passing
from active surgical excision through to surveillance and
then returning to surgical intervention for early targeting of
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Table 4: Malignant transformation of dysplastic precursor lesions.
Number of dysplastic lesions Study period (yrs) Malignant transformation (%)
Silverman et al. (1984) [9] 22 7 36.4
Hogewind et al. (1989) [13] 84 5 3.6
Lumerman et al. (1995) [14] 44 3 16
Schepman et al. (1998) [15] 166 24 12
Cowan et al. (2001) [16] 165 20 14
Holmstrup et al. (2006) [17] 87 20 12
Hsue et al. (2007) [18] 166 10 4.8
Ho et al. (2009) [19] 33 10 24
Arduino et al. (2009) [20] 207 16 7.2
Liu et al. (2011) [12] 138 5 26.8
Warnakulasuriya et al. (2011) [8] 204 9 11.7
Ho et al. (2012) [11] 91 5 25.3
Brouns et al. (2013) [7] 56 4 14.3
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Figure 5: Kaplan-Meier analysis plotting disease-free survival for
further (new site) disease and further disease-free patients (𝑃 =
0.0001, Log-Rank test).
further PMD disease. A particular advantage of laser surgery
is the ability to repeat excisions or ablations at the same site on
a number of occasions, without compromising oral healing or
function [2, 10].
5. Conclusions
In this study, 62% of PMD patients were disease-free fol-
lowing laser excision of dysplastic mucosal lesions, and
the risk of malignant transformation remained low at 2 to
5%. The incidence of further disease, however, increased
with the length of patient followup, and was higher for
non-homogeneous leukoplakias, large mucosal lesions, more
severe dysplasias, floor of mouth and ventral tongue sites,
and in nonsmoking patients. Long-term patient followup and
active clinical surveillance thus remains mandatory for all
PMD patients. Multicentre, randomised controlled clinical
trials for PMD treatment are now urgently required to
determine treatment efficacy.
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for (same site) malignant transformation and malignant transfor-
mation-free patients (𝑃 = 0.0001, Log-Rank test).
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